Target Pipelines
Subscribe to
our newsletters!
Showing 21–40 of 50 results
- This product provides basic information on immunotherapy candidates in research and development targeting mesothelin€ 300.00
- This product provides basic information on therapeutic antibodies in R&D targeting C-C chemokine receptor type 8 (CCR8).€ 300.00
- This product provides basic information on drug candidates in research and development targeting CD40 or CD40 ligand€ 300.00
- This product provides basic information on drug & imaging candidates in R&D targeting Fibroblast Activation Protein (FAP)€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D targeting folate receptor alpha (FRα)€ 300.00
- This product provides basic information on approved drugs and immunotherapy candidates in R&D targeting IGF-1 or its receptor (IGF-1R)€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Prolia & Xgeva (denosumab).€ 300.00
- This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Humira (adalimumab).€ 400.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Soliris (eculizumab).€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Xolair (omalizumab).€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Lucentis (ranibizumab)€ 300.00
- This product provides basic information on drug candidates in R&D as biosimilar antibodies of Eylea (aflibercept)€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Stelara (ustekinumab).€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D targeting thymic stromal lymphopoietin (TSLP) or its receptor (TSLP-R).€ 300.00
- Antibody Target, Technology & Pipeline Database€ 1600.00
- This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.€ 1800.00
- The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
- The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00
- This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00